UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D/A

Under the Securities Exchange Act of 1934

(Amendment No. 4)*

Nuveen Real Asset Income & Growth Fund

(Name of Issuer)

Common Shares, $0.01 par value

(Title of Class of Securities)

67074Y105

(CUSIP Number)

Saba Capital Management, L.P.

405 Lexington Avenue

58th Floor

New York, NY 10174

Attention: Michael D'Angelo

(212) 542-4635
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

January 16, 2024

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box. [ ]

(Page 1 of 8 Pages)

______________________________

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No.  67074Y105 SCHEDULE 13D/A Page 2 of 8 Pages

1	NAME OF REPORTING PERSON      Saba Capital Management, L.P.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP		(a) ☐ (b) ☐
3	SEC USE ONLY
4	SOURCE OF FUNDS      OO (see Item 3)
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)		☐
6	CITIZENSHIP OR PLACE OF ORGANIZATION      Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:	7	SOLE VOTING POWER      -0-
	8	SHARED VOTING POWER      2,498,743
	9	SOLE DISPOSITIVE POWER      -0-
	10	SHARED DISPOSITIVE POWER      2,498,743
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON      2,498,743
12	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES		☐
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)      9.11%
14	TYPE OF REPORTING PERSON      PN; IA

The percentages used herein are calculated based upon 27,416,679 shares of common stock outstanding as of 6/30/23, as disclosed in the company's N-CSRS filed 9/6/23

CUSIP No.  67074Y105 SCHEDULE 13D/A Page 3 of 8 Pages

1	NAME OF REPORTING PERSON      Boaz R. Weinstein
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP		(a) ☐ (b) ☐
3	SEC USE ONLY
4	SOURCE OF FUNDS      OO (see Item 3)
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)		☐
6	CITIZENSHIP OR PLACE OF ORGANIZATION      United States
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:	7	SOLE VOTING POWER      -0-
	8	SHARED VOTING POWER      2,498,743
	9	SOLE DISPOSITIVE POWER      -0-
	10	SHARED DISPOSITIVE POWER      2,498,743
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON      2,498,743
12	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES		☐
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)      9.11%
14	TYPE OF REPORTING PERSON      IN

The percentages used herein are calculated based upon 27,416,679 shares of common stock outstanding as of 6/30/23, as disclosed in the company's N-CSRS filed 9/6/23

CUSIP No.  67074Y105 SCHEDULE 13D/A Page 4 of 8 Pages

1	NAME OF REPORTING PERSON      Saba Capital Management GP, LLC
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP		(a) ☐ (b) ☐
3	SEC USE ONLY
4	SOURCE OF FUNDS      OO (see Item 3)
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)		☐
6	CITIZENSHIP OR PLACE OF ORGANIZATION      Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:	7	SOLE VOTING POWER      -0-
	8	SHARED VOTING POWER      2,498,743
	9	SOLE DISPOSITIVE POWER      -0-
	10	SHARED DISPOSITIVE POWER      2,498,743
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON      2,498,743
12	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES		☐
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)      9.11%
14	TYPE OF REPORTING PERSON      OO

The percentages used herein are calculated based upon 27,416,679 shares of common stock outstanding as of 6/30/23, as disclosed in the company's N-CSRS filed 9/6/23

CUSIP No.  67074Y105 SCHEDULE 13D/A Page 5 of 8 Pages

Item 1.	SECURITY AND ISSUER
	This Amendment No. 4 amends and supplements the statement on Schedule 13D filed with the SEC on 8/14/23, as amended by Amendment No.1 filed 9/29/23, Amendment No.2 filed 11/10/23 and Amendment No.3 filed 12/5/23; with respect to the common shares of Nuveen Real Asset Income & Growth Fund. This Amendment No. 4 amends Items 3, 4, 5, 6 and 7, as set forth below.

Item 3.

SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION

Funds for the purchase of the Common Shares were derived from the subscription proceeds from investors and the capital appreciation thereon and margin account borrowings made in the ordinary course of business.  In such instances, the positions held in the margin accounts are pledged as collateral security for the repayment of debit balances in the account, which may exist from time to time.  Since other securities are held in the margin accounts, it is not possible to determine the amounts, if any, of margin used to purchase the Common Shares reported herein. A total of approximately $28,002,150 was paid to acquire the Common Shares reported herein.

Item 4.

PURPOSE OF TRANSACTION

On January 16, 2024, Saba Capital Master Fund, Ltd., a private fund advised by Saba Capital, submitted to the Issuer a notice of intent informing the Issuer of its intention to nominate Jason Chen (the "Nominee") as an independent trustee for election to the Board at the Issuer's 2024 annual meeting of shareholders.  The Nominee has entered into a nomination agreement (the "Nominee Agreement") with Saba Capital substantially in the form attached as Exhibit 3 to this Schedule 13D/A whereby the Nominee agreed to stand for election as a trustee of the Issuer in connection with a proxy solicitation which may be conducted in respect of the 2024 Annual Meeting and whereby, Saba Capital has agreed to defend and indemnify the Nominee against, and with respect to, any losses that may be incurred by the Nominee in the event he becomes a party to litigation based on his nomination as a candidate for election to the Board and the solicitation of proxies in support of his election. The foregoing summary of the Nominee Agreement is not complete and is qualified in its entirety by reference to the full text of the form of Nominee Agreement, a copy of which is attached as Exhibit 3 and is incorporated by reference herein.

Item 5.	INTEREST IN SECURITIES OF THE ISSUER
(a)	See rows (11) and (13) of the cover pages to this Schedule 13D/A for the aggregate number of Common Shares and percentages of the Common Shares beneficially owned by each of the Reporting Persons.  The percentages used herein are calculated based upon 27,416,679 shares of common stock outstanding as of 6/30/23, as disclosed in the company's N-CSRS filed 9/6/23

CUSIP No.  67074Y105 SCHEDULE 13D/A Page 6 of 8 Pages

(b)	See rows (7) through (10) of the cover pages to this Schedule 13D/A for the number of Common Shares as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.
(c)	The transactions in the Common Shares effected since the Schedule 13D/A filing on 12/5/23 by the Reporting Persons, which were all in the open market, are set forth in Schedule A, and are incorporated herein by reference.
(d)	The funds and accounts advised by Saba Capital have the right to receive the dividends from and proceeds of sales from the Common Shares.
(e)	Not applicable.
Item 6.	CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER
	Item 6 is hereby amended and supplemented by the addition of the following:
	The Reporting Persons' response to Item 4 is incorporated by reference into this Item 6.

Item 7.	MATERIAL TO BE FILED AS EXHIBITS
Exhibit 3:	Form of Nominee Agreement

CUSIP No.  67074Y105 SCHEDULE 13D/A Page 7 of 8 Pages

SIGNATURES

After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Date:  January 18, 2024

	SABA CAPITAL MANAGEMENT, L.P.  By:  /s/ Michael D'Angelo
	Name: Michael D'Angelo Title: Chief Compliance Officer
	SABA CAPITAL MANAGEMENT GP, LLC  By:  /s/ Michael D'Angelo Name:Michael D'Angelo Title:Authorized Signatory
	BOAZ R. WEINSTEIN  By:  /s/ Michael D'Angelo
	Name: Michael D'Angelo
	Title: Attorney-in-fact*
* Pursuant to a power of attorney dated as of November 16, 2015, which is incorporated herein by reference to Exhibit 2 to the Schedule 13G filed by the Reporting Persons on December 28, 2015, accession number: 0001062993-15-006823

CUSIP No.  67074Y105 SCHEDULE 13D/A Page 8 of 8 Pages

Schedule A

This Schedule sets forth information with respect to each purchase and sale of Common Shares which were effectuated by Saba Capital since the filing of the Schedule 13D/A on 12/5/23.  All transactions were effectuated in the open market through a broker.

Trade Date	Buy/Sell	Shares	Price
12/5/2023	Buy	1,519	11.24
12/6/2023	Buy	7,884	11.33
12/12/2023	Buy	3,366	11.32
12/14/2023	Buy	22,368	11.85
1/2/2024	Buy	6,110	11.78
1/3/2024	Buy	22,971	11.87
1/4/2024	Buy	34,143	11.94
1/8/2024	Sell	(38,623)	11.93
1/16/2024	Buy	12,657	11.69